	US 11,813,337 B2
	Tumor-targeting synthetic adenoviruses and uses thereof
Clodagh O'Shea, San Diego, CA (US); Colin Powers, San Diego, CA (US); and Lei Zhang, San Diego, CA (US)
Assigned to Salk Institute for Biological Studies, La Jolla, CA (US)
Filed by Salk Institute for Biological Studies, La Jolla, CA (US)
Filed on Jun. 7, 2019, as Appl. No. 16/434,714.
Application 16/434,714 is a continuation of application No. PCT/US2017/065604, filed on Dec. 11, 2017.
Claims priority of provisional application 62/433,140, filed on Dec. 12, 2016.
Prior Publication US 2019/0314523 A1, Oct. 17, 2019
Int. Cl. A61K 48/00 (2006.01); A61P 35/00 (2006.01); C12N 7/00 (2006.01); C12Q 1/66 (2006.01)

CPC A61K 48/005 (2013.01) [A61P 35/00 (2018.01); C12N 7/00 (2013.01); C12Q 1/66 (2013.01); C12N 2799/022 (2013.01); C12Y 113/12007 (2013.01); G01N 2800/7028 (2013.01)]

24 Claims

1. A method of expressing a transgene in stromal cells in a tumor, comprising infecting the stromal cells in the tumor with a synthetic adenovirus comprising:

the transgene inserted into the E1 region, wherein the transgene encodes an anti-cancer agent;

a native or modified capsid that detargets the synthetic adenovirus from the liver; and an adenovirus type 34 (Ad34) fiber protein or a chimeric fiber protein comprising an adenovirus type 5 (Ad5) shaft domain and an Ad34 knob domain,

wherein the stromal cells in the tumor express the transgene.